igf 1 lr3 swolverine IGF-1 1mg Superior Peptide IGF-1 LR3 GROWTH

It is for researchers and study-readers orienting themselves in this literature

Peer review Peer review information Nature Metabolism thanks the anonymous reviewers for their contribution to the peer review of this work

Phase 2 cagrilintide alone ~10.8% body weight reduction at 26 weeks (4.5mg) Phase 2 CagriSema combo ~15.6% body weight reduction at 32 weeks Phase 3 REDEFINE 1 ~22.7% body weight reduction at 68 weeks Phase 2 CagriSema combination trial The Phase 2 trial of CagriSema was published in The Lancet in 2023, and its results attracted immediate attention

Each assay was done in triplicate and each experiment was done three times